Mineralocorticoid Receptor Antagonists in Dialysis
American Journal of Nephrology · 15.04.2026 · 1-19
DOI: 10.1159/000551881 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift American Journal of Nephrology, online erschienen am 15.04.2026. Verfasst von Elias John Elenjickal und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, McGill University Health Center, Montreal, Québec, Canada. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 136 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background: Aldosterone regulates genes controlling fluid and electrolyte balance through mineralocorticoid receptor (MR) activation. Sustained MR activation promotes inflammation, fibrosis, sodium retention, and myocardial remodeling. MR antagonists (MRAs) block aldosterone binding in the kidney, heart, and vasculature and are classified as steroidal or nonsteroidal. Although large, randomized trials have confirmed the benefits of steroidal MRAs in heart failure and of finerenone in diabetic kidney disease, these pivotal studies systematically excluded patients with kidney failure receiving dialysis. Over the past decade, several phase 2 and 3 trials have evaluated MRAs in dialysis, yielding heterogeneous and sometimes conflicting results. This review summarizes the biological rationale, evolving clinical evidence, and future directions for MR blockade in dialysis. Summary: Pharmacokinetic studies indicate that spironolactone and eplerenone are highly protein-bound, hepatically metabolized, and not dialyzable, supporting cautious use in dialysis with potassium monitoring. Early randomized trials from East Asia suggested potential cardiovascular benefit with spironolactone 25 mg daily; however, these studies were underpowered and reported relatively few outcome events. More definitive evidence is now available from two large multicenter randomized controlled trials. In ALCHEMIST (n = 644), spironolactone 25 mg daily did not reduce major adverse cardiovascular events compared with placebo over a median follow-up of 2.7 years [hazard ratio (HR) 1.00, 95% confidence interval (CI) 0.73–1.36]. Similarly, in ACHIEVE (n = 2,538), spironolactone failed to reduce the composite of cardiovascular death or hospitalization for heart failure (HR 0.92, 95% CI: 0.78–1.09) over 1.8 years and was associated with higher rates of hyperkalemia. A contemporary meta-analysis incorporating these trials confirmed neutral efficacy but higher rates of asymptomatic hyperkalemia and gynecomastia. Key Messages: Current evidence indicates that steroidal MRAs confer no cardiovascular or survival benefit in maintenance dialysis and modestly increase the risk of hyperkalemia and endocrine adverse effects.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, McGill University Health Center, Montreal, Québec, Canada.
- Research Institute of the McGill University Health Center, Montreal, Québec, Canada.
- Department of Nephrology, Christian Medical College, Vellore, India.
- Department of Medicine, McGill University Health Center, Montreal, Québec, Canada, thomas.mavrakanas@mcgill.ca.
- Research Institute of the McGill University Health Center, Montreal, Québec, Canada, thomas.mavrakanas@mcgill.ca.
Zitieren
APA
Elenjickal, E. J., & Mavrakanas, T. A. (2026). Mineralocorticoid Receptor Antagonists in Dialysis. American Journal of Nephrology, 1-19. https://doi.org/10.1159/000551881
Vancouver
Elenjickal EJ, Mavrakanas TA. Mineralocorticoid Receptor Antagonists in Dialysis. American Journal of Nephrology. 2026:1-19. doi:10.1159/000551881
BibTeX
@article{Elenjickal2026,
author = {Elenjickal, Elias John and Mavrakanas, Thomas A},
title = {Mineralocorticoid Receptor Antagonists in Dialysis},
journal = {American Journal of Nephrology},
year = {2026},
pages = {1--19},
doi = {10.1159/000551881}
}
EUVIMED